Prothena Corporation plc Ordinary Shares (PRTA) is a publicly traded Healthcare sector company. As of May 21, 2026, PRTA trades at $9.95 with a market cap of $502.07M and a P/E ratio of -3.28. PRTA moved +3.14% today. Year to date, PRTA is +2.75%; over the trailing twelve months it is +28.26%. Its 52-week range spans $4.32 to $20.75. Analyst consensus is buy with an average price target of $21.40. Rallies surfaces PRTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prothena Advances Lead Candidate to Phase 1 While Securing Cash Runway Into 2027: Prothena reported first quarter 2026 financial results and noted sufficient cash runway into 2027 to fund ongoing programs. The company advanced its lead immuno-neurology candidate into Phase 1 trials and secured a new collaboration for its amyloid-targeting research.
| Metric | Value |
|---|---|
| Price | $9.95 |
| Market Cap | $502.07M |
| P/E Ratio | -3.28 |
| EPS | $-2.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.75 |
| 52-Week Low | $4.32 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $57.94M |
| Net Income | $-151.18M |
| Gross Margin | 0.00% |
5 analysts cover PRTA: 0 strong buy, 3 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.40.